Notably, previous studies have demonstrated that GHRH antagonists can downregulate KRAS and COX-2 expression while inhibiting PI3K/Akt and NF-κB signaling in NSCLC models [13,31]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.